1-9 of 9
Michael Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Jo Raskin, Alexis B. Cortot, Santiago Viteri, Julien Mazieres, Egbert F. Smit, Michael Thomas, Wade T. Iams, Byoung Chul Cho, Hye Ryun Kim, James Chih-Hsin Yang, Yuh-Min Chen, Jyoti D. Patel, Christine M. Bestvina, Keunchil Park, Frank Griesinger, Melissa Johnson, Maya Gottfried, Christian Britschgi, John Heymach, Elif Sikoglu, Karin Berghoff, Karl-Maria Schumacher, Rolf Bruns, Gordon Otto, Paul K. Paik
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1117–1126.
https://doi.org/10.1158/1078-0432.CCR-21-2733
Published: 15 March 2022
View article titled, Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Open the PDF for Tepotinib Efficacy and Safety in Patients with <em>MET</em> Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice in another window
Includes: Supplementary data
Journal Articles

Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer

Steffen Dietz, Petros Christopoulos, Lisa Gu, Volker Endris, Zhao Yuan, Simon J. Ogrodnik, Tomasz Zemojtel, Marc A. Schneider, Anna-Lena Volckmar, Michael Meister, Thomas Muley, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A21.
https://doi.org/10.1158/1557-3265.LiqBiop20-A21
Published: 01 June 2020
View article titled, Abstract A21: Longitudinal analysis of cell-free DNA for therapy monitoring of ALK-positive non-small cell lung cancer
Journal Articles

Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, Vladimir Hanes
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (10): 3193.
https://doi.org/10.1158/1078-0432.CCR-19-1098
Published: 15 May 2019
View article titled, Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study
Open the PDF for Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study in another window
Journal Articles

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Nicholas Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, Vladimir Hanes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (7): 2088–2095.
https://doi.org/10.1158/1078-0432.CCR-18-2702
Published: 01 April 2019
View article titled, Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study
Open the PDF for Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study in another window
Journal Articles

Abstract 29: Characterization and treatment of a novel adoptive transfer model of Sf3b1mut/Atmdel chronic lymphocytic leukemia

Elisa ten Hacken, Lili Wang, Fara Faye Regis, Michael Thomas, Jing Deng, Kaitlyn Baranowski, Zachary Cartun, Silvia Buonamici, Donna Neuberg, Anthony Letai, Ruben Carrasco, Catherine J. Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 29.
https://doi.org/10.1158/1557-3265.HEMMAL17-29
Published: 14 December 2017
View article titled, Abstract 29: Characterization and treatment of a novel adoptive transfer model of Sf3b1<sup>mut</sup>/Atm<sup>del</sup> chronic lymphocytic leukemia
Journal Articles

Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer

Marc A. Schneider, Martin Granzow, Arne Warth, Philipp A. Schnabel, Michael Thomas, Felix J.F. Herth, Hendrik Dienemann, Thomas Muley, Michael Meister
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (15): 3529–3540.
https://doi.org/10.1158/1078-0432.CCR-14-2464
Published: 02 August 2015
View article titled, Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Open the PDF for Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A26: Imprime PGG improves the efficacy of carboplatin, paclitaxel, and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).

Michael Thomas, Parvis Sadjadian, Jens Kollmeier, Zhonglin Hao, Myra Patchen, Jamie Lowe, Paulette Mattson, Richard D. Huhn, Nandita Bose, Mary Antonysamy, Michele Gargano, Keith Gordon, Folker Schneller
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2_Supplement): A26.
https://doi.org/10.1158/1078-0432.14AACRIASLC-A26
Published: 16 January 2014
View article titled, Abstract A26: Imprime PGG improves the efficacy of carboplatin, paclitaxel, and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).
Journal Articles

Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer

Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith, Claudia M. Espitia, Anthony Possemato, Sean A. Beausoleil, Michael Milhollen, Stephen Blakemore, Michael Thomas, Allison Berger, Jennifer S. Carew
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3577–3590.
https://doi.org/10.1158/1078-0432.CCR-12-3212
Published: 30 June 2013
View article titled, Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Open the PDF for Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer

Nicolas J. Dickgreber, Thomas H. Fink, Jane E. Latz, Anwar M. Hossain, Luna C. Musib, Michael Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 382–389.
https://doi.org/10.1158/1078-0432.CCR-08-0128
Published: 31 December 2008
View article titled, Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer
Open the PDF for Phase I and Pharmacokinetic Study of Pemetrexed plus Cisplatin in Chemonaive Patients with Locally Advanced or Metastatic Malignant Pleural Mesothelioma or Non–Small Cell Lung Cancer in another window